Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma 1

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Standard of Care 10Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Capecitabine 7Surveys and Questionnaires 6Gemcitabine 6Cyclophosphamide 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Radiotherapy 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diphenhydramine × Tumor-Agnostic × 90 days × Clear all
NCT05977998 2026-05-22

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡